Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The effect of maintenance remifentanil infusion with target controlled infusion during laryngeal mask airway removal on hemodynamic parameters and emergence quality is going to be investigated.
In all patients (control group and remifentanil group induction of anesthesia will be achieved with desflurane and remifentanil.Anesthesia will be maintained with remifentanil (1-4 ng/mL) by TCI target controlled infusion, and desflurane . Throughout the surgery hemodynamic parameters are going to be recorded. As soon as the surgery has been finished, in control group remifentanil infusion and desflurane inhalation is going to be stopped.In remifentanil group,desflurane inhalation is going to be stopped and remifentanil infusion will be maintained until the removal of LMA. During the emergence period the time of eye opening, hemodynamic parameters and emergence quality (score 1-2)are going to be recorded.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ultiva,remifentanil,opioid,analgesic | Active Comparator | Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery |
|
| control | No Intervention | Control:Remifentanil stopped at the end of the surgery |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| remifentanil | Drug | 1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Smooth cLMA Removal Condition (Score 1) | cLMA removal was accepted as successful (score 1) if none of the complications coughing, teeth clenching, gross purposeful movements, breath holding, laryngospasm, and desatura- tion to SpO2\90% was observed. If any of these compli- cations was observed it was regarded as unsuccessful (score 2) | At the end of the surgery |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jülide Ergil, MD | Ministry of Health Dıskapi Yildirim Beyazit Training and Research Hospital, Anesthesiology 1. | Study Chair |
| Alp Alptekin, MD | Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital, Anesthesiology 1 | Study Chair |
| Nihan Aktürk, MD | Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital , Anesthesiology 1 | Study Chair |
| Haluk Gümüs, MD | Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital, Anesthesiology 1 | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ministry of Health Diskapi Yildirim Beyazit Research and Training Hospital departement of 1. Anesthesiology | Ankara | 06110 | Turkey (Türkiye) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19864308 | Result | Nho JS, Lee SY, Kang JM, Kim MC, Choi YK, Shin OY, Kim DS, Kwon MI. Effects of maintaining a remifentanil infusion on the recovery profiles during emergence from anaesthesia and tracheal extubation. Br J Anaesth. 2009 Dec;103(6):817-21. doi: 10.1093/bja/aep307. Epub 2009 Oct 28. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Ultiva,Remifentanil,Opioid,Analgesic | Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery |
| FG001 | Control | Control:Remifentanil stopped at the end of the surgery |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Ultiva,Remifentanil,Opioid,Analgesic | Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery |
| BG001 | Control | Control:Remifentanil stopped at the end of the surgery |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Smooth cLMA Removal Condition (Score 1) | cLMA removal was accepted as successful (score 1) if none of the complications coughing, teeth clenching, gross purposeful movements, breath holding, laryngospasm, and desatura- tion to SpO2\90% was observed. If any of these compli- cations was observed it was regarded as unsuccessful (score 2) | Posted | Number | percentage of participants | At the end of the surgery |
|
During the surgery
serious and/or other [non-serious] adverse events were not collected/assessed.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Remifentanil Group | remifentanil group (group R) TCI effect-site of remifentanil at 1.5 ng/ml was continued until cLMA removal |
Not provided
Not provided
The limitation of our study is age and ASA status of the included patients'. The relatively older or ASA status III,IV population may interfere the effect-site concentration TCI of remifentanil
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Derya Özkan MD | Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital 1. Anesthesiology | 0903125962553 | derya_z@yahoo.com |
Not provided
| ID | Term |
|---|---|
| D000077208 | Remifentanil |
| ID | Term |
|---|---|
| D011422 | Propionates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
| 0 |
| 0 |
| 0 |
| 0 |
| EG001 | Control Group | Remifentanil stopped at the end of the surgery | 0 | 0 | 0 | 0 |
Not provided
Not provided
| D010880 |
| Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |